Coherus BioSciences

333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States

Tel: 800-794-5434

About Coherus BioSciences

We are committed to making high-value biosimilars affordable for everyone. It’s an unconventional approach to business that defines who we are and what we do.

At Coherus, we hold ourselves to a higher standard. We don’t break the rules—we write our own.

In early 2021, we expanded our mission into immuno-oncology with a collaboration with Shanghai Junshi Biosciences for the development and commercialization of toripalimab, Junshi Biosciences’ novel anti-PD-1 antibody, in the United States and Canada.

We are embarking on a new phase in our evolution, focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Join us, as we seek to break down barriers and make a difference in patients’ lives.

Stock Symbol: CHRS

Stock Exchange: NASDAQ

192 articles with Coherus BioSciences

Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September 2021 Issue of Nature Medicine

9/15/2021

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd announced publication of a cover article in the September issue of Nature Medicine featuring clinical data from the pivotal study “JUPITER-02”, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

9/13/2021

Coherus Biosciences, Inc. (Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced the presentation today of positive interim results from the pivotal study “CHOICE-01” (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC) without driver mutations.
Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

9/10/2021

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 23rd Annual H.C. Wainwright Global Investment Conference. The presentation will be made available at 7 a.m. ET on Tuesday, September 14, 2021, during the virtual conference.
Coherus BioSciences Announces Upcoming Medical Conference Presentations

9/8/2021

Coherus BioSciences, Inc. today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at the European Society for Medical Oncology Congress 2021.
Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

9/1/2021

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) announced today the completion of the rolling submission of the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for toripalimab.
Coherus BioSciences Announces New Employment Inducement Grants - Aug 27, 2021

8/27/2021

Coherus BioSciences, Inc., announced that effective Aug. 26, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 278,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $15.82, the closing trading price on the grant date.
NSCLC Drug Improves Progression-Free Survival in Late-Stage Trial

8/19/2021

Junshi Biosciences announced that the Phase III clinical trial it is conducting alongside Coherus BioSciences on a potential non-small cell lung cancer drug shows positive preliminary results.
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma

8/12/2021

Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. today announced that the United States Food and Drug Administration (“FDA”) has recently granted Breakthrough Therapy Designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the 1 st line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

8/5/2021

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for the quarter ended June 30, 2021.
Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

7/26/2021

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021.
Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

7/21/2021

Coherus BioSciences, Inc. today announced the appointment of Ildiko Csiki, M.D., Ph.D., a leader in the field of immuno-oncology research and drug development, as Chair of its Scientific Advisory Board (SAB).
Coherus BioSciences Announces New Employment Inducement Grants - July 13, 2021

7/13/2021

Coherus BioSciences, Inc., announced that effective July 6, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of the common stock of the Company to newly hired employees with a per share exercise price of $13.63, the closing trading price on the grant date.
ASCO Update: A Theme of Accessibility and Pricing Plus Individual Reporting

6/4/2021

With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
Coherus BioSciences to Present at the Bank of America Health Care Conference

5/7/2021

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST.
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress

5/6/2021

Junshi Biosciences transaction is followed by rapid toripalimab progress including initiation of first BLA submission to the U.S. FDA, positive interim analysis in pivotal esophageal cancer trial, and selection for ASCO plenary session
Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th

4/30/2021

Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its first quarter 2021 financial results will be released after market close on Thursday, May 6, 2021. Starting at 4:30 p.m. ET,
Coherus BioSciences Announces New Employment Inducement Grants - Apr 30, 2021

4/30/2021

Coherus BioSciences, Inc., announced that effective April 28, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 483,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $14.76, the closing trading price on the grant date.
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting- Toripalimab data will also be featured in ASCO’s official press program -

4/29/2021

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc., announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021.
Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting

4/29/2021

Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that a late-breaking abstract detailing clinical data of anti-PD-1 antibody, toripalimab, in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma will be featured at ASCO 2021 in the plenary session on Sunday, June 6, 2021.
Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

4/23/2021

Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC),